Nirynya Jitarayameth

Ms. Nirynya Jitarayameth

Dermatology, Srinakharinwirot University, Bangkok, Krung Thep Maha Nakhon, Thailand
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2026 in Cosmetics
Verified
Journal Article
Open access
PDF file
NJNirynya Jitarayameth
Nirynya Jitarayameth
NFNanticha Faromkao
Nanticha Faromkao
CLChotinij Lertphanichkul
Chotinij Lertphanichkul
CMChantalck Muennarong
Chantalck Muennarong
MUMontree Udompataikul
Montree Udompataikul
Background: Seborrheic dermatitis is a chronic, relapsing inflammatory condition requiring acute and maintenance treatment. Ectoine, a natural extremolyte with barrier-supportive and anti-inflammatory properties, offers a potential non-steroidal option. Methods: In this double-blind randomized controlled trial, 40 participants received 7% ectoine or 1% hydrocortisone cream twice daily for up to 4 weeks. Responders entered a 12-week maintenance phase and were re-randomized to ectoine or placebo. Outcomes included change in Seborrheic Dermatitis Area and Severity Index (SEDASI) from baseline, Investigator’s Global Assessment (IGA), remission and relapse rates, time to relapse, and adverse events. Results: SEDASI decreased from baseline in both groups. The reduction was larger with hydrocortisone, but the between-group mean difference at Week 4 was −2.01 (95% CI, −4.81 to 0.78; p = 0.151). Median time to relapse was 56 versus 28 days with ectoine and placebo, respectively (log-rank p = 0.066). Adverse events were mild. Conclusions: Overall, 7% Ectoine reduced disease severity during the acute phase, though numerically less than 1% hydrocortisone; the non-significant difference does not exclude a clinically relevant advantage of hydrocortisone. Ectoine showed a non-significant trend toward longer time to relapse.